People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and ...

The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others People taking popular new ...

A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

This article was reviewed by Darragh O’Carroll, MD. Long-Term Side Effects of Wegovy® Key takeaways: The long-term side ...

Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as the ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs ...

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...